The technology is a dye that lights up tumors.
Philip Low is the co-founder of the West Lafayette based company, On Target Laboratories. The company raised $40,000,000 to further this technology.
Eventually, Johnson & Johnson expressed interest. Now the company has the funds to finish the studies for FDA approval.
"We believe that it will change the practice of surgery, we've designed a bright florescent dye and linked it to one of these homing molecules that homes in on cancer tissue," said Low.
The dye is injected in cancer patients intravenously, surgeons are able to see more, therefore remove more cancer.
Dr. Ruban Nirmalan is a surgeon at IU Health Arnett and said he's excited for the technology.
"It will definitely decrease the amount of times that we have to go in and take out more tissue, which obviously for the patient is beneficial because it's going to be one surgery instead of two," said Nirmalan.
So what comes next?
"The money we raised is going to be used to complete the studies necessary for FDA approval for the use of this dye first in ovarian cancer, then in lung cancer," said Low.